Scientists have found that GLP-1 medications, such as Ozempic, and Wegovy, is linked to a decrease in the overall risk of ...

In a large observational study of adults with obesity without diabetes, GLP-1 receptor agonists were associated with a 41% lower incidence of obesity-associated cancers over 2 years.

Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

New research suggests GLP-1 drugs could reduce cancer risk. A doctor breaks down how that could change public health in the ...

New research breaks it down.

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously ...

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO ...

Most people know that obesity increases risk for developing diabetes, heart disease, and high blood pressure; however, what ...

MALAGA, Spain—Among patients with obesity or diabetes, the long-term incidence of cancer related to excess body weight doesn’t differ between those treated with an early-generation glucagon-like ...

Obesity, recognized as a complex and growing health issue, is associated with an increased risk of various cancers. A comprehensive review appearing in Frontiers of Medicine provides insights into the ...

Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide. While genetics and age are well-known risk factors, growing evidence highlights a significant connection ...

Obesity and stress could magnify the risk of one of the most aggressive types of cancer, a new study suggests. Researchers at University of California Los Angeles (UCLA) found that stress-related ...